




RealRate

PHARMACEUTICAL 2023

Lipella Pharmaceuticals INC
Rank 167 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lipella Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipella Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Lipella Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 309%, being 65% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	5,799
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,178
Liabilities, Non-Current	96
Other Assets	151
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-8.0
Other Revenues	184
Property and Equipment	0
Research and Development	2,548
Selling, General and Administrative Expense	226

Output Variable	Value in 1000 USD
Assets	5,950
Liabilities	1,275
Expenses	2,774
Revenues	184
Stockholders Equity	4,676
Net Income	-2,598
Comprehensive Net Income	-2,598
BaseVar	5,095
ECR before LimitedLiability	210%
Economic Capital Ratio	309%